OVERLAND PARK, Kan.—(BUSINESS WIRE)—Dr. Vince Clinical Research (DVCR), a contract research organization specializing in early phase trials, announced the first dosing in a Phase II multi-center trial of SPN-820 in adults with major depressive disorder (MDD). DVCR is...
OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), a full-service Phase I-II contract research organization (CRO) announced a new solution to conduct renal and hepatic impairment studies. The solution leverages trusted relationships...
Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom study. This study is taking place in...
Strategic collaboration amplifies accessibility to Clario’s Early Precision QT (EPQT) methodology, enabling biopharmaceutical firms to secure more accurate and cost-efficient cardiac safety data in early clinical development stages. Meticulous multi-stage evaluation...
OVERLAND PARK, Kan.; August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study...
OVERLAND PARK, Kan.; June 27, 2023 (Business Wire) – Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes...
Recent Comments